GlassScriptPhysician profile
Agnes Kallon
NPI 1043536790
$3,937.14
in general payments reported to CMS, 2019-2025
37 companies · $586 in 2025
The $586 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $2,046 · 2023: $436 · 2024: $44.13 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592 · Long Term Medical Supply Or Device Loan: $299 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.89 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $643.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $570.14 | 2021-2023 | Reblozyl |
| Celgene Corporation | $380.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.98 | 2022 | |
| Exelixis INC. | $203.71 | 2024-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $202.71 | 2021-2022 | |
| Beone Medicines USA, INC. | $165.33 | 2025 | Tevimbra |
| Eisai INC. | $145.32 | 2021-2022 | |
| Amgen INC. | $145.03 | 2021-2022 | |
| Genzyme Corporation | $143.10 | 2022 | |
| Merck Sharp & Dohme LLC | $140.11 | 2021-2025 | Keytruda |
| Lilly USA, LLC | $138.63 | 2021-2025 | Verzenio, Jaypirca |
| Epizyme, INC. | $123.36 | 2021 | |
| Janssen Biotech, INC. | $117.06 | 2021-2025 | Darzalex, Tecvayli |
| Taiho Oncology, INC. | $56.77 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $44.75 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $43.06 | 2021-2022 | |
| Abbvie INC. | $36.69 | 2022 | |
| Caris Mpi, INC. | $29.07 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $29.00 | 2025 | Monjuvi, Zynyz |
| Myriad Genetic Laboratories, INC. | $27.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.87 | 2022 | |
| G1 Therapeutics, INC. | $24.15 | 2022 | |
| Spectrum Pharmaceuticals INC. | $22.71 | 2025 | Rolvedon |
| Tersera Therapeutics LLC | $21.79 | 2022 | |
| Acrotech Biopharma INC. | $21.22 | 2025 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $21.22 | 2022 | |
| Daiichi Sankyo INC. | $20.81 | 2022 | |
| Astellas Pharma US INC | $19.87 | 2022 | |
| Beigene USA, INC. | $19.80 | 2022 | |
| Pfizer INC. | $18.92 | 2022 | |
| Global Blood Therapeutics, INC. | $18.75 | 2022 | |
| Organon LLC | $18.49 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.87 | 2021 | |
| Coherus Oncology, INC. | $15.42 | 2024 | |
| Array Biopharma INC | $14.30 | 2022 | |
| Emd Serono, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Kallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.